source
- FDA approves Egetis Therapeutics' Emcitate for rare X linked disease shortening life expectancy to 35 yearsEgetis Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its drug Emcitate. The therapy is intended for patients with a rare X linked genetic disorder that…
- Regulators Discuss Plans to Streamline Europe’s Drug Approval Process at 2026 RAPS ConvergenceA panel of European regulators gathered at the 2026 RAPS Convergence in Charlotte, North Carolina to discuss ongoing initiatives aimed at simplifying the continent’s regulatory framework. The offi…